PMGC Holdings Inc. Following Skincare Subsidiary Sale, Embarks on Bold Growth Strategy

Core Insights - PMGC Holdings Inc. has announced a strategic divestiture of its skincare subsidiary, Elevai Skincare, to enhance shareholder value and operational efficiency [1][2] - The sale is aimed at maximizing immediate financial benefits while positioning the company for future growth through structured royalties and milestone payments [2][4] - This divestiture aligns with PMGC's strategy to focus on transformative acquisitions that drive substantial growth and shareholder value [3][5] Financial and Operational Highlights - The divestiture has led to a reduction in cash burn by eliminating a loss-generating subsidiary, resulting in a leaner operational framework [4] - PMGC will receive approximately $1.1 million in stock from Carmell Corporation and retain a 5% royalty on skincare revenues over the next five years [4] - The company plans to redirect resources into high-potential assets, leveraging its expertise to create shareholder value [4][6] Strategic Vision - PMGC is committed to exploring accretive acquisitions and licensing opportunities in sectors with significant growth potential [7] - The company aims to identify undervalued assets that align with its vision of building a diversified and growth-oriented portfolio [7][9] - Current subsidiaries include Elevai Biosciences, Elevai Research, and PMGC Capital LLC, reflecting the company's focus on innovation and growth [10]